Cognetivity Neurosciences Sees Scientific Paper Outline Strong Use-Case For Integrated Cognitive Assessment Test

Cognetivity Neurosciences (CSE: CGN) this morning announced that it has seen another publication of a scientific paper on its assessment tool for early-stage Alzheimer’s. Referred to by the company as an Integrated Cognitive Assessment, or ICA, the firm indicates that the peer-reviewed paper provides further evidence of the benefits of the tool.

The paper itself reportedly demonstrates the “sensitivity to early-stage Alzheimer’s Disease, freedom from cultural or educational bias and suitability for remote patient monitoring,” that the assessment tool offers. Furthermore, it further validates the use of the tool as a digital cognitive biomarker, which is effective at identifying mild cognitive impairment and Alzheimer’s disease, particularly at mild or early stages.

One of the key benefits of the ICA, as outlined within the scientific paper, is that the platform performs consistently in international populations, where traditionally there have been limitations due to language and culture-specific data. The result is that the tool can be effectively deployed at scale rapidly, without the need to collect additional data.

Lastly, it was also highlighted that the tool works excellent as a remote cognitive assessment, without the loss of testing accuracy. This feature in particular makes the platform an excellent option for high-frequency monitoring both at clinics and at home.

The diagnostic accuracy of the ICA and its novel use of explainable AI, combined with the power to generalize across other languages and cultures, make it uniquely suitable for cognitive screening across large and diverse populations. And in light of the FDA’s recent approval of the disease-modifying drug aducanumab, the need for a device capable of screening a wide population of at-risk individuals has never been higher.

Professor Dag Aarsland, co-author of the scientific paper

The full scientific paper can be reviewed here.

Cognetivity Neurosciences last traded at $1.07 on the CSE.


FULL DISCLOSURE: Cognetivity Neurosciences Ltd is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Cognetivity Neurosciences Ltd on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

2026 Could Be Gold’s Biggest Year Yet!? | Ryan King – Equinox Gold

Gold Is Screaming Higher While Currencies Burn | Simon Ridgway – Rackla Metals

We Have the Highest-Grade Antimony Deposit in North America!? | Jim Atkinson -Antimony Resources

Recommended

Canadian Copper Secures $8 Million Lead Order From Ocean Partners As Part Of Larger Funding Round

Northern Superior Expands Philibert With 350 Metre Step Out Testing 1.10 g/t Gold Over 25.5 Metres

Related News

Cognetivity To Deploy Flagship Assessment Tool At Florida-Based Clinic

The rollout of Cognetivity Neurosciences’ (CSE: CGN) flagship product, the CognICA cognitive assessment tool, continues....

Wednesday, May 25, 2022, 07:53:15 AM

Cognetivity Sees Pilot Program Transition Into Commercial Agreement In UAE

A successful pilot program has lead to a commercial arrangement for Cognetivity Neurosciences (CSE: CGN)....

Wednesday, June 15, 2022, 07:23:20 AM

Cognetivity’s Brain Health Monitoring App – The Daily Dive

On this Daily Dive episode, Cassandra talks to Dr. Sina Habibi, CEO of Cognetivity Neurosciences...

Friday, November 19, 2021, 03:28:00 PM

Cognetivity Reaches First Commercial Agreement In Middle East

Cognetivity Neurosciences (CSE: CGN) has seen the deployment of its technology to a new region...

Wednesday, September 22, 2021, 09:41:33 AM

Cognetivity Neurosciences Selected For Accelerator Program To Fast Track US Commercialization

Cognetivity Neurosciences (CSE: CGN) has been selected as one of just seven members of the...

Wednesday, December 23, 2020, 09:08:31 AM